REV-MED announced its participation in the 23rd Federation of Asian Veterinary Associations Congress (FAVA 2024), held from October 25 to 27, according to a statement released on the 31st.
Co-hosted by the Federation of Asian Veterinary Associations and the Korean Veterinary Medical Association, the congress served as a platform for renowned experts in veterinary medicine to share the latest trends and insights while fostering networking among professionals in the field.
This year’s event welcomed 2,000 to 3,000 veterinary professionals and related organizations from 24 countries, underscoring the growing importance of veterinarians in areas like biosecurity and One Health initiatives. The event highlighted active exchanges between academia and industry, fostering innovations that benefit humans, animals, and the environment alike.
At the exhibition, REV-MED showcased its TriCell PRP and PRP UNI products, introducing their capabilities to numerous experts.
In the veterinary medical market, the field of cell therapy—which involves the extraction and concentration of specific cells, including stem cells—is experiencing significant growth.
A company representative noted, "Therapeutic products used for humans undergo validation through animal testing during their development phase. Since the treatment approaches for humans and animals are largely similar, these products can be effectively applied to a variety of pet ailments, offering the potential for extending their healthy lifespan."
They further stated, "With increasing interest in pet anti-aging and disease management, the market size is expected to expand gradually. These technologies can be safely and effectively applied to various fields, including the management of refractory skin diseases in pets, alongside the orthopedic market."
Source: DailyMedi https://www.dailymedi.com/news/news_view.php?wr_id=918010
REV-MED announced its participation in the 23rd Federation of Asian Veterinary Associations Congress (FAVA 2024), held from October 25 to 27, according to a statement released on the 31st.
Co-hosted by the Federation of Asian Veterinary Associations and the Korean Veterinary Medical Association, the congress served as a platform for renowned experts in veterinary medicine to share the latest trends and insights while fostering networking among professionals in the field.
This year’s event welcomed 2,000 to 3,000 veterinary professionals and related organizations from 24 countries, underscoring the growing importance of veterinarians in areas like biosecurity and One Health initiatives. The event highlighted active exchanges between academia and industry, fostering innovations that benefit humans, animals, and the environment alike.
At the exhibition, REV-MED showcased its TriCell PRP and PRP UNI products, introducing their capabilities to numerous experts.
In the veterinary medical market, the field of cell therapy—which involves the extraction and concentration of specific cells, including stem cells—is experiencing significant growth.
A company representative noted, "Therapeutic products used for humans undergo validation through animal testing during their development phase. Since the treatment approaches for humans and animals are largely similar, these products can be effectively applied to a variety of pet ailments, offering the potential for extending their healthy lifespan."
They further stated, "With increasing interest in pet anti-aging and disease management, the market size is expected to expand gradually. These technologies can be safely and effectively applied to various fields, including the management of refractory skin diseases in pets, alongside the orthopedic market."
Source: DailyMedi https://www.dailymedi.com/news/news_view.php?wr_id=918010